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We performed a prospective study to evaluate the efﬁcacy and safety of secondary antifungal prophylaxis
(SAP) for patients with a history of invasive pulmonary aspergillosis (IPA) in allogeneic hematopoietic stem
cell transplantation (allo-HSCT). In this study, the prophylactic agents used were chosen based on treatment
response to initial antifungal therapy. One hundred and thirty-six patients undergoing allo-HSCT with prior
IPA were enrolled in this multicenter study. The agents of SAP included itraconazole in 24, voriconazole in 74,
caspofungin in 32, and liposomal amphotericin B in 6. Eighty-eight patients had stable IPA and 48 had active
IPA at the time of transplantation. The success rate of SAP was 91.2%. Twelve patients developed breakthrough
invasive fungal disease (IFD), and none discontinued antifungal agents because drug-related adverse events.
The incidence of breakthrough IFD was neither different among the different antifungal agents (P ¼ .675) nor
between patients with active and stable IPA (P ¼ .080). The 1-year cumulative incidence of IFD and IPA relapse
was 27.3%  4.5% and 24.7%  4.4%, respectively. Our data indicate that SAP with antifungal agents based on
initial antifungal therapy has favorable efﬁcacy and safety in allo-HSCT recipients with prior IPA. Active IPA
might not increase the risk of breakthrough IFD after transplantation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION treatment response to initial antifungal therapy. The efﬁcacy
Invasive fungal disease (IFD) is a serious and common
complication in patients undergoing allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT), leading to
considerable morbidity and mortality. Patients with prior
IFD, especially with a history of invasive pulmonary asper-
gillosis (IPA), are subject to an unacceptable risk of infection
relapse and death after transplantation [1-3]. Historically,
prior IPA constituted a relative contraindication to allo-HSCT
[4,5]. Recently, new antifungal agents, with advances in ac-
tivity against Aspergillus and side effects have signiﬁcantly
improved the outcomes of fungal infection [6]. A growing
body of clinical evidence shows that secondary antifungal
prophylaxis (SAP) could reduce the risk of IFD recurrence and
transplantation-related mortality [3,7-10]. Consequently,
most patients with prior IFD nowmight receive allo-HSCT in
the context of SAP [8,9,12-14]. However, the optimal agents
for SAP have not beenwell deﬁned until now. In addition, it is
still a matter of discussion whether transplantations can be
performed in patients with active IPA. In this prospective
study, antifungal agents for SAP were chosen based onedgments on page 1202.
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14.04.016and safety of this strategy were assessed. Moreover, we
compared the outcome of SAP between patients with stable
IPA and active IPA.
METHODS
IFD Diagnosis and Entry Criteria
This was a prospective, open-labeled, multicenter study. According to
the revised European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group; National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria [11], IPA
was deﬁned as radiographic ﬁndings compatible with IFD on computed
tomography (CT) scan plus 1 of the following: (1) Aspergillus identiﬁed by
biopsy, (2) Aspergillus identiﬁed from culture of bronchoalveolar lavage
ﬂuids, or (3) positive ﬁnding of serum galactomannan (GM) test (>.5 ng/
mL1). Patients with a history of proven or probable IPA before trans-
plantation were eligible for this study. Patients were excluded if they had 1
of the following: (1) no response to initial antifungal treatment, (2) drug-
related toxicity caused by the antifungal agent used in initial antifungal
treatment or intolerance to the agents, (3) liver dysfunction (bilirubin or
transaminase level> 3 times the upper limit of normal) or renal impairment
(creatinine clearance rate < 30 mL/minute), or (4) possible IPA. The study
was performed in accordance with the modiﬁed Helsinki Declaration, and
the protocol was approved by Nanfang Hospital ethical review boards before
study initiation. All patients and donors provided written informed consent.
Patients and Transplantation
Between January 2007 and June 2013, 136 patients with a history of IPA
were enrolled in this study at Nanfang Hospital, Guangzhou General Hos-
pital of Guangzhou Command, and SUN Yat-sen Memorial Hospital. Fifty
were female and 86 were male. The median age was 33 (range, 14 to 57)Transplantation.
Table 1
Demographic and Clinic Characteristics of the Patients
Characteristic Stable IPA
(n ¼ 88)
Active IPA
(n ¼ 48)
P Value
Age, median (range), yr 30 (14-53) 36 (20-57) .074
Gender .896
Male 56 (63.6%) 30 (62.5%)
Female 32 (36.4%) 18 (37.5%)
Stage of underlying primary
diseases
<.001
CR 70 (79.5%) 17 (35.4%)
Non-CR 18 (20.5%) 31 (64.6%)
Diagnosis of prior IPA .770
Proven 13 (14.8%) 8 (16.7%)
Probable 75 (85.2%) 40 (83.3%)
Duration of initial treatment
of IPA
.992
Median (range), d 98 (22-338) 92 (20-220)
Donor .945
Related 61 (69.3%) 33 (68.8%)
Unrelated 27 (30.7%) 15 (31.2%)
HLA type .217
Matched 64 (72.7%) 30 (62.5%)
Mismatched 24 (27.3%) 18 (37.5%)
Conditioning regimen .009
Standard 50 (56.8%) 16 (33.3%)
Intensiﬁed 38 (43.2%) 32 (66.7%)
ATG for aGVHD prophylaxis 40 (45.5%) 26 (54.2%) .331
IPA indicates invasive pulmonary aspergillosis; ATG, antithymocyte glob-
ulin; CR, complete remission; aGVHD, acute graft-versus-host disease.
Data presented are n (%), unless otherwise indicated.
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transplantation. The underlying primary diseases included leukemia in 122,
lymphoma in 7, myelodysplastic syndrome in 6, and severe aplastic anemia
in 1. For their initial treatment of IPA, 21 patients received itraconazole, 72
received voriconazole, 31 received caspofungin, 6 received liposomal
amphotericin B (L-AmB), and 6 received a combination of 2 agents (ie,
itraconazole and L-AmB in 3, voriconazole and L-AmB in 2, caspofungin and
L-AmB in 1). The median duration of antifungal treatment before trans-
plantation was 98 days (range, 20 to 338 days).
Ninety-four patients underwent transplantation from a related donor
and 42 from an unrelated donor. HLA-matched transplantations were
conducted in 94 patients and HLA-mismatched transplantations were
conducted in 42. In the patients with unrelated donors, 24 received HLA-
matched and 18 received HLA-mismatched transplantations. Sixty-six
patients received standard conditioning and 70 received intensiﬁed condi-
tioning. The regimens of conditioning had been described in previous study
[12]. Graft-versus-host disease (GVHD) prophylaxis and treatment were
administered according to the strategy previously described [12].
Antifungal Prophylaxis and Treatment
The SAP agents were chosen based on the treatment responses to initial
antifungal therapy: the same antifungal agent that was previously used and
proven effective in initial antifungal therapy was administered as the SAP
agent. Itraconazole was given intravenously with a loading dose of 200 mg
every 12 hours for 4 doses, followed by maintenance doses of 200 mg every
24 hours until neutrophil engraftment and then switched to 200 mg every
12 hours orally. Voriconazole was given intravenously with a loading dose of
6 mg/kg every 12 hours (for 2 doses), followed by maintenance doses of
4 mg/kg every 12 hours until neutrophil engraftment and then switched to
200 mg every 12 hours orally. Caspofungin was given intravenously at a
loading dose of 70 mg every 24 hours (for 1 dose) followed by maintenance
doses of 50 mg every 24 hours. L-AmB was given at a dose of 150 mg daily.
For patients with itraconazole, voriconazole, or caspofungin, the dose was
reduced by one half if bilirubin was above the normal threshold but < 2
times the upper limit of normal; the agent was switched to another anti-
fungal agent, as deemed appropriate by the attending physician, if bilirubin
was > 2 times the upper limit of normal. For patients with L-AmB, the dose
was reduced to 50 mg if creatinine was above the normal threshold but < 2
times the upper limit of normal; L-amB was changed to another antifungal
agent if creatinine was > 2 times the upper limit of normal. SAP was given
from the start of the conditioning until 90 days after transplantation in
patients with stable IPA before transplantation or until eradication or sta-
bility of residual foci in the patients with active IPA. The agent that was used
in SAP was given for prophylaxis again when patients developed acute
GVHD (aGVHD) were treated with corticosteroids and/or monoclonal anti-T
cell antibodies. Generally, antifungal prophylaxis was not administered in
patients receiving immunosuppressive treatment for chronic GVHD
(cGVHD). Once breakthrough IFD was diagnosed, antifungal therapy would
be modiﬁed. The patients using triazoles for prophylaxis were switched to
echinocandins or L-AmB (3 mg/kg) for treatment, and those with prophy-
lactic echinocandins or L-AmB were switched to one of the other 2 kinds of
antifungal agents. If IFD occurred after the end of prophylaxis, patients were
treated with the antifungal agent that was used for prophylaxis.
Monitoring
Generally, serum concentration of GM and b-D-glucan (G test) of all
patients were monitored once each week and a CT scan was done once each
month during the SAP. The GM test was performed in the Department of
Laboratory Medicine, Nanfang Hospital and the G test was performed in the
respective hospitals. If a patient was suspected of developing IFD during the
prophylaxis or after the end of prophylaxis, a G test, GM test, and CT were
performed. A blood culture, bronchoalveolar lavage of ﬂuids, and biopsy of
involved areas were performed according to clinical indications.
Deﬁnitions
Responses to treatment were classiﬁed into complete responses (CR),
partial responses (PR), stable responses, and failure of therapy, as evaluated
in the clinical trials [13,14]. CR and PR were considered effective. Patients
with stable IPA at transplantation were those who achieved CR after initial
antifungal treatmentdno fungal lesion by CT detection or no 18 F-ﬂuo-
rodeoxyglucose high uptake in residual pulmonary lesion by positron
emission tomography/CT [15-17], as well as negative GM test. Active IPAwas
deﬁned as PR or stable responses to prior IFD at transplantations. Break-
through IFD was deﬁned as a new episode of fungal infection or the recur-
rence of fungal infection during the SAP [18]. IPA relapse was deﬁned as the
recurrence of IPA, which occurred during and after prophylaxis, caused by
the same Aspergillus, including expansion of residual lesion or occurrence of
new lesion other than historic lesion. A positive ﬁnding of GM test withoutclinical signwas not considered IPA relapse. IFD-related mortality was death
due to IFD or toxicity of antifungal agents. The stages of the underlying
primary diseases were evaluated according to consensus criteria [19-23];
patients with severe aplastic anemia were considered in non-CR (complete
remission) stage at transplantation.
STATISTICAL CONSIDERATIONS
The data were analyzed on December 31, 2013. The pri-
mary endpoint, success of SAP, was deﬁned as absence of
breakthrough IFD (proven, probable, and possible) during
SAP and no premature discontinuation of study agents
because of drug-related adverse events. Secondary end-
points consist of the incidence of post-transplantation IFD
(including breakthrough IFD and IFD that occurred after the
end of SAP), adverse events, IFD-related mortality, and sur-
vival. IFD that occurred after salvage therapy for relapse of
underlying primary disease was not included as post-
transplantation IFD. Continuous variables were compared
by the Mann-Whitney test. For categorical variables, the chi-
square statistic or Fisher exact test were used to establish the
difference of distribution between groups. Cumulative inci-
dence of IPA and overall survival (OS) were estimated by the
Kaplan-Meier procedure and comparison was done by a log-
rank test. A Cox proportional hazards regression model was
used for analysis of risk factors for breakthrough and post-
transplantation IFD as well as for OS. All P values were
2-sided. P values < .05 were considered to indicate statistical
signiﬁcance. The statistics was performed by the software
SPSS (Chicago, IL).
RESULTS
Baseline Characteristics of the Patients and Prior IPA
Of the 136 patients enrolled in study, IPAwas proven in 21
and probable in 115 patients. Eight-eight patients had stable
IPA and 48 had active IPA at the time of their transplantation.
Fourteen patients had cavity lesions or a nodule more than
2 cm in diameter, and 8 of these patients received
Table 2
Breakthrough Proven IFD after Transplantation
Patients Organism Prophylactic Agent MIC of Prophylactic Agent, mg/mL Treatment Response
1 Fusarium Itraconazole 1 L-AmB NR
2 Zygomycete voriconazole 4 L-AmB PR
3 C.tropicalis Itraconazole .5 caspofungin CR
MIC indicates minimum inhibitory concentration; NR, no response; PR, partial response; CR, complete response.
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resections, 2 with lobectomies). The demographic and
transplantation characteristics were similar between the
patients with stable and active IPA, except for the stage of
underlying primary diseases at the time of transplantation
and intensity of conditioning regimen (Table 1).Outcome of Transplantation
Hematopoietic engraftment was achieved in all patients
except for 1, who died of intracranial hemorrhage on dayþ13
after transplantation before hematopoietic reconstitution.
Forty-six patients developed grade II to IV aGVHD, and 55
patients developed cGVHD (limited, n ¼ 32; extensive,
n ¼ 23). Thirty-six patients developed underlying primary
diseases relapse after transplantation.Antifungal Prophylaxis and Efﬁcacy
Itraconazole (n ¼ 24), voriconazole (n ¼ 74), caspofungin
(n ¼ 32), and L-AmB (n ¼ 6) were administered for SAP. The
median duration of SAP was 96 days (range, 13 to 237 days).
One hundred and twenty-four patients completed SAP with
the success rate was 91.2%. Twelve patients (8.8%) developed
breakthrough IFD and none discontinued antifungal agents
because of drug-related adverse events. The pathogens of the
new infections were Fusarium, Zygomycete, and C. tropicalis,
respectively (Table 2). Breakthrough IFD occurred at a me-
dian time of day þ41 after transplantation (range, day þ14
to þ166). Five patients developed breakthrough IFD during
aGVHD. The incidence of breakthrough IFD in the patients
with itraconazole, voriconazole, caspofungin, and L-AmB
were 12.5% (3 of 24), 8.1% (6 of 74), 9.4% (3 of 32) and 0% (0 of
6), respectively, and were not different among the different
antifungal agents (P ¼ .675). The incidence of breakthrough
IFD was 5.7% (5 of 88) and 14.6% (7 of 48), in the patients
with stable and active IPA before transplantation, respec-
tively (P ¼ .080).Figure 1. The 1-year cumulative incidence of post-transplantation IFD in
recipients with stable or active IPA at transplantation.Incidence of Post-transplantation IFD
Within a median follow-up of 337.5 days after trans-
plantation (range, 13 to 2481 days), 33 patients developed
IFD, including the 12 aforementioned during the period of
prophylaxis and 21 after the end of prophylaxis. The 1-year
cumulative incidence of IFD was 27.3%  4.5%. The inci-
dence of IFD in the patients with stable IPA at transplantation
was lower than that in the patients with active IPA
(22.8%  5.1% versus 41.6%  9.1%, P ¼ .026) (Figure 1). In
these patients, 27 presented IPA relapse at a median of
day þ137.5 (range, day þ14 to þ533), including 9 during the
prophylaxis and 18 after the end of SAP; 6 patients developed
a new episode of fungal infection, including 3 during the
prophylaxis and 3 after the end of SAP. The pathogens of the
new infections after the end of SAP were C .tropicalis and
Fusarium spp. Among cGVHD patients, 8 developed IPA
relapse. The 1-year cumulative incidence of IPA relapse was
24.7%  4.4%.Toxicity and Tolerance
No patients discontinued antifungal agents because of
drug-related adverse events. Fifty-three patients developed
hepatic or renal toxicity with mild intensity. Bilirubin was
increased but it was below 2 times the upper limit of normal
in 48 (35.3%) patients, including 18 (13.2%) caused by the
antifungal agents (4 with itraconazole, 12 with voriconazole,
and 2with caspofungin). Six patients using L-AmB developed
increased creatinine (<2 times the upper limit of normal)
during the SAP. After a dosage reduction and symptomatic
treatment, the increased bilirubin and creatinine all returned
to normal level.
Treatment and Outcome of Post-transplantation IFD
Thirty patients who developed post-transplantation IFD
received salvage therapy, whereas 3 abandoned treatment
because of concomitant primary disease relapse. Three
patients received itraconazole, 6 received voriconazole, 3
received caspofungin, and 18 received L-AmB for treatment.
After salvage therapy,13 patients achieved CR and 8 achieved
PR. Nine of the 30 patients died of IFD, leading to a cumu-
lative IFD-related mortality of 9.8%  3.3%. The IFD-related
mortality was 19.9%  8.2% in patients with active IPA
before transplantation, which was signiﬁcantly higher than
in those with stable IPA (5.3%  3.0%, P ¼ .041).
Risk Factors for IFD
The potential risk factors for breakthrough IFD and post-
transplantation IFD are presented in Table 3. None of the
potential risk factors were associated with breakthrough
IFD. Two factors were found to increase the risk of post-
transplantation IFD on both univariate and multivariate
analysis: active IPA at the time of transplantation (hazard
Table 3
Risk Factors for Breakthrough IFD and Post-transplantation IFD
Risk Factors Breakthrough IFD Post-transplantation IFD
Univariate Multivariate (HR) Univariate Multivariate (HR)
Status of underlying primary disease at the time of transplantation, non-CR versus CR NS NS NS NS
IPA stage at HSCT, stable versus active NS NS .006 (2.400) .015 (2.407)
Duration of antifungal treatment pre-transplantation,  90 d versus < 90 d NS NS NS NS
Donor type, unrelated versus related NS NS NS NS
HLA type, mismatched versus matched NS NS NS NS
Conditioning regimen, standard versus intensiﬁed NS NS NS NS
ATG used in GVHD prophylaxis NS NS NS NS
Neutrophil engraftment NS NS NS NS
aGVHD, grade II to IV versus grade 0 to I NS NS NS NS
Use of corticosteroids and/or monoclonal anti-T cell antibody NS NS NS NS
cGVHD, extensive versus no/limited NS NS NS NS
Immunosuppressive treatment for cGVHD (>1 mo) NS NS .040 (2.166) .039 (2.173)
CMV infection* NS NS NS NS
Relapse of underlying primary diseases NS NS NS NS
NS indicates not signiﬁcant; IFD, invasive fungal disease, CR, complete remission, IPA, invasive pulmonary aspergillosis; HSCT, hematopoietic stem cell trans-
plantation; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease;
CMV, cytomegalovirus; HR, hazard ratio.
* CMV infection included viremia and end organ diseases.
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P ¼ .015) and immunosuppressive treatment for cGVHD
(longer than 1 month) (HR, 2.173; 95% CI, 1.039 to 4.542;
P ¼ .039).Survival
At the end of follow-up, 63 patients were alive and 73
died. The causes of death included relapse of underlying
primary diseases (n ¼ 31), GVHD (n ¼ 10), bacterial infection
(n ¼ 10), viral infection (n ¼ 9), IFD (n ¼ 9), post-
transplantation intracerebral hemorrhage (n ¼ 3), and
lymphoproliferative disorder (n ¼ 1). The 1-year OS after
allo-HSCT was 58.1%  4.5%. The 1-year OS in the patients
with active IPA before transplantationwas lower than that in
patients with stable IPA (40.7%  7.5% versus 67.8%  5.3%,
P < .001) (Figure 2). Among patients in CR stage of primary
disease at transplantation, the 1-year OS was 59.6%  12.9%
and 75.2% 5.6% in the active and stable groups, respectively
(P ¼ .322); for those in non-CR stage of primary disease at
transplantation, the 1-year OS in active and stable group wasFigure 2. Overall survival in recipients with active or stable IPA at
transplantation.30.2%  8.7% and 41.2%  11.9%, respectively (P ¼ .256)
(Figure 3).
Risk factors for OS are presented in Table 4. Three vari-
ables were associated with lower OS on a Cox regression
model: stage of underlying primary diseases at trans-
plantation (non-CR) (HR, 2.650; 95% CI, 1.566 to 4.483;
P < .001), grade II to IV aGVHD (HR, 1.896; 95% CI, 1.127 to
3.190; P ¼ .016), and relapse of underlying primary diseases
(HR, 4.008; 95% CI, 2.371 to 6.775; P < .001).DISCUSSION
SAP has been reported to improve the prognosis of pa-
tients with a history of IFD in allo-HSCT [3,7,9,24]. In patients
with IFD history undergoing allo-HSCT, 2 retrospective
studies demonstrated the incidence of IFD was 22% to 29%,
despite SAP with itraconazole, ﬂuconazole, L-AmB [2,25]. A
prospective study showed that the 1-year incidence of IFD
was 7% in allo-HSCT recipients who received prophylactic
voriconazole with a median duration of 94 days and 4.4% of
patients were withdrawn because of drug-related adverseFigure 3. Overall survival in recipients in CR or non-CR stage of primary
diseases at the time of transplantation. Among patients in CR stage of primary
diseases, the 1-year OS was not signiﬁcantly different between active and
stable IPA group (Active IPA 59.6% versus Stable IPA 75.2%, P ¼ .322); for those
in non-CR stage of primary diseases, the 1-year OS in active IPA and stable
group were 30.2% and 41.2%, respectively (P ¼ .256).
Table 4
Risk Factors for Overall Survival
Risk Factors Univariate Multivariate
(HR)
Status of underlying primary
disease at the time of
transplantation, non-CR versus CR
NS <.001 (2.650)
IPA stage at HSCT, stable versus active NS NS
Donor type, unrelated versus related NS NS
HLA type, mismatched versus matched NS NS
Conditioning regimen, standard versus
intensiﬁed
NS NS
Neutrophil engraftment NS NS
aGVHD, grade II to IV versus 0 to I .018 (2.120) .016 (1.896)
cGVHD, extensive versus no/limited NS NS
Post-transplantation IFD NS NS
Relapse of underlying primary diseases <.001 (3.952) <.001 (4.008)
NS indicates not signiﬁcant; CR, complete remission, IPA, invasive pulmo-
nary aspergillosis; HSCT, hematopoietic stem cell transplantation; aGVHD,
acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease;
IFD, invasive fungal disease; HR, hazard ratio.
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caspofungin and itraconazole for SAP in patients undergoing
chemotherapy or HSCT; the results showed that the rate of
breakthrough IFD was 32% and the incidence of withdrawal
because of drug-related adverse events in patients with
caspofungin or itraconazole were 0% and 4.3%, respectively. It
was notable that the majority of the studies were single-arm
trials or focused on the comparison of 2 agents, and pro-
phylaxis failure due to drug-related toxicity was observed
[5,7,9,26]. For overcoming prophylaxis failure, it is theoreti-
cally feasible to use the agent that has been proven effective
and well tolerated in initial antifungal therapy for SAP. In this
study, we chose the agents based on response to initial
antifungal therapy as secondary prophylaxis. Our results
showed that the success rate of SAP was 91.2% and no patient
discontinued antifungal agents because of drug-related
adverse events. The incidence of breakthrough IFD was
8.8% and similar in patients with different agents. Based on
these results, we suggest that this strategy might be effective
and safe.
Some studies suggested the risk factors for IFD relapse
after transplantation included non-CR status of underlying
primary disease, short interval between initial antifungal
therapy and HSCT, non-CR stage of prior IFD, stem cell source
(bone marrow or cord blood), use of myeloablative condi-
tioning regimens, and severe aGVHD [2,25]. In view of evi-
dence from retrospective and small-sampled studies, conﬂict
exists on whether active IPA increases the risk of relapse
[1,2,27]. In this prospective study, patients with active IPA
had similar incidence of IFD to those with stable IPA during
SAP, which might be attributed to the choice of prophylactic
agents based on drug susceptibility proven in initial therapy.
However, a higher incidence of IFD after the end of prophy-
laxis was found in patients with active IPA. Our analysis of
the risk factors for post-transplantation IFD demonstrated
that active IPA at transplantation increased risk of IPA. These
results implied that patients with active IPA before trans-
plantation might need prolonged antifungal prophylaxis.
Nevertheless, active IPA before transplantation and post-
transplantation IFD were not risk factors for lower OS in
our cohorts. Active IPA does not seem to increasemortality in
patients at CR stage of primary diseases nor in those at
non-CR stage. This indicates that allo-HSCT was feasible for
recipients with active IPA before transplantation when
effective prophylaxis and salvage therapy were given.Besides, the long-term use of immunosuppressive treatment
for cGVHD was a risk factor that was associated with post-
transplantation IFD. Based on this ﬁnding, antifungal pro-
phylaxis might be considered when patients develop cGVHD
and receive long-term immunosuppressive treatment.
Some reports suggested that surgery might be effective in
decreasing risk of IPA relapse in patients who had IPA of large
nodules or a cavity in the lung before transplantation [28,29].
Consistent with those results, 8 patients undergoing surgery
before transplantation did not experience relapse after
transplantation in our study. However, IPA relapse after
transplantation developed in 2 patients of 6 who did not
have surgery because of underlying primary diseases (non-
CR) or multiple sites of lesions.
The main drawback of this study was that most of pa-
tients were diagnosed as probable IFD according to imaging
and GM test. The percentage of proven IFD was relatively low
(21 of 136,15.4%). The low percentage of proven IFD is mainly
limited by the potential risk of an invasive biopsy and low
platelet count attributed to chemotherapy before trans-
plantation in the patients with hematological malignancies.
In conclusion, SAP with agents chosen based on initial
antifungal therapy might be effective and safe. Active IPA at
the time of transplantation might not increase the risk of
breakthrough IFD during SAP.
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